NG004 in Spinal Cord Injury Patients

Drug

General health

Online since 24 May 2025, updated 10 days ago

About this trial

This trial is enrolling at least 12 (up to 21) participants with acute incomplete cervical spinal cord injury to test the safety of repeated NG004 injections (6 injections; 1 every 5 days) into the fluid around the spinal cord. NG004 is an antibody that targets Nogo-A, a protein that inhibits nerve growth. If included, participants will receive one of three different doses of NG004. Final testing of safety and tolerability will be performed after 6 months.

Included participants

Gender

All

Age

18 - 70 years

Injury level

C1 - C8

Severity (AIS)?

AIS-C

AIS-D

Time since injury

4 days - 28 days

Injury type

Traumatic

Healthy volunteers

C1-C8

Additionally, participants must

NOT have history of acute episode of Multiple Sclerosis or Guillian-Barre syndrome.

What’s involved

Type

Drug

Details

- Participants will receive repeated NG004 injections (6 injections; 1 every 5 days) into the fluid around the spinal cord. - NG004 is an antibody that targets Nogo-A, a protein that inhibits nerve growth. - Final testing of safety and tolerability will be performed after 6 months.

Potential benefits

Main benefits

General health

Additional benefits

Arm/hand function

Sensory function

Standing/walking/mobility

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results